Tokyo Tape
Sign in
← GNI Group

Quarterly report · Q3

2160.TEDINET S100PN1P
Period2022-01-01 → 2022-09-30
Filed2022-11-14
StandardIFRS
ConsolidatedYes
Data checks16 of 16 passed
Key figures · 62
MetricValuePeriodScopeSource row
Revenue¥12.8bn2022-01-01 → 2022-09-30Cons.Revenue IFRS
Revenue¥4.6bn2022-07-01 → 2022-09-30dCons.Revenue IFRS
Revenue¥12.7bn2021-01-01 → 2021-12-31Cons.Revenue IFRS (5-year summary)
Revenue¥9.5bn2021-01-01 → 2021-09-30Cons.Revenue IFRS
Revenue¥3.1bn2021-07-01 → 2021-09-30dCons.Revenue IFRS
Operating income¥1.5bn2022-01-01 → 2022-09-30Cons.Operating profit loss IFRS
Operating income¥490m2022-07-01 → 2022-09-30dCons.Operating profit loss IFRS
Operating income¥2.0bn2021-01-01 → 2021-09-30Cons.Operating profit loss IFRS
Operating income¥505m2021-07-01 → 2021-09-30dCons.Operating profit loss IFRS
Profit before tax¥1.2bn2022-01-01 → 2022-09-30Cons.Profit loss before tax IFRS
Profit before tax¥433m2022-07-01 → 2022-09-30dCons.Profit loss before tax IFRS
Profit before tax¥1.1bn2021-01-01 → 2021-12-31Cons.Profit loss before tax IFRS (5-year summary)
Profit before tax¥1.6bn2021-01-01 → 2021-09-30Cons.Profit loss before tax IFRS
Profit before tax¥371m2021-07-01 → 2021-09-30dCons.Profit loss before tax IFRS
Net income (owners)¥1.1bn2022-01-01 → 2022-09-30Cons.Profit loss attributable to owners of parent IFRS
Net income (owners)¥400m2022-07-01 → 2022-09-30dCons.Profit loss attributable to owners of parent IFRS
Net income (owners)¥1.1bn2021-01-01 → 2021-12-31Cons.Profit loss attributable to owners of parent IFRS (5-year summary)
Net income (owners)¥1.3bn2021-01-01 → 2021-09-30Cons.Profit loss attributable to owners of parent IFRS
Net income (owners)¥353m2021-07-01 → 2021-09-30dCons.Profit loss attributable to owners of parent IFRS
Net income¥324m2022-01-01 → 2022-09-30Cons.Profit loss IFRS
Net income¥126m2022-07-01 → 2022-09-30dCons.Profit loss IFRS
Net income¥55m2021-01-01 → 2021-12-31Cons.Profit loss IFRS (5-year summary)
Net income¥875m2021-01-01 → 2021-09-30Cons.Profit loss IFRS
Net income¥130m2021-07-01 → 2021-09-30dCons.Profit loss IFRS
Total assets¥36.5bnat 2022-09-30Cons.Assets IFRS
Total assets¥30.3bnat 2021-12-31Cons.Assets IFRS
Total assets¥29.8bnat 2021-09-30Cons.Total assets IFRS (5-year summary)
Total liabilities¥14.4bnat 2022-09-30Cons.Liabilities IFRS
Total liabilities¥11.0bnat 2021-12-31Cons.Liabilities IFRS
Net assets / equity¥22.0bnat 2022-09-30Cons.Equity IFRS
Net assets / equity¥19.3bnat 2021-12-31Cons.Equity IFRS
Net assets / equity¥19.4bnat 2021-09-30Cons.Equity IFRS
Net assets / equity¥12.8bnat 2020-12-31dCons.Equity IFRS
Equity (owners)¥22.9bnat 2022-09-30Cons.Equity attributable to owners of parent IFRS
Equity (owners)¥18.9bnat 2021-12-31Cons.Equity attributable to owners of parent IFRS
Equity (owners)¥18.5bnat 2021-09-30Cons.Equity attributable to owners of parent IFRS (5-year summary)
Cash & equivalents¥12.7bnat 2022-09-30Cons.Cash and cash equivalents IFRS
Cash & equivalents¥14.4bnat 2021-12-31Cons.Cash and cash equivalents IFRS
Cash & equivalents¥13.9bnat 2021-09-30Cons.Cash and cash equivalents IFRS
Cash & equivalents¥10.3bnat 2020-12-31dCons.Cash and cash equivalents IFRS
Operating cash flow−¥163m2022-01-01 → 2022-09-30Cons.Net cash provided by used in operating activities IFRS
Operating cash flow¥552m2021-01-01 → 2021-12-31Cons.Cash flows from used in operating activities IFRS (5-year summary)
Operating cash flow¥755m2021-01-01 → 2021-09-30Cons.Net cash provided by used in operating activities IFRS
Investing cash flow−¥2.9bn2022-01-01 → 2022-09-30Cons.Net cash provided by used in investing activities IFRS
Investing cash flow−¥261m2021-01-01 → 2021-12-31Cons.Cash flows from used in investing activities IFRS (5-year summary)
Investing cash flow−¥884m2021-01-01 → 2021-09-30Cons.Net cash provided by used in investing activities IFRS
Financing cash flow−¥299m2022-01-01 → 2022-09-30Cons.Net cash provided by used in financing activities IFRS
Financing cash flow¥2.9bn2021-01-01 → 2021-12-31Cons.Cash flows from used in financing activities IFRS (5-year summary)
Financing cash flow¥3.2bn2021-01-01 → 2021-09-30Cons.Net cash provided by used in financing activities IFRS
EPS (basic)¥22.672022-01-01 → 2022-09-30Cons.Basic earnings loss per share IFRS
EPS (basic)¥8.422022-07-01 → 2022-09-30dCons.Basic earnings loss per share IFRS
EPS (basic)¥22.722021-01-01 → 2021-12-31Cons.Basic earnings loss per share IFRS (5-year summary)
EPS (basic)¥27.692021-01-01 → 2021-09-30Cons.Basic earnings loss per share IFRS
EPS (basic)¥7.442021-07-01 → 2021-09-30dCons.Basic earnings loss per share IFRS
EPS (diluted)¥22.462022-01-01 → 2022-09-30Cons.Diluted earnings loss per share IFRS
EPS (diluted)¥8.282022-07-01 → 2022-09-30dCons.Diluted earnings loss per share IFRS
EPS (diluted)¥22.082021-01-01 → 2021-12-31Cons.Diluted earnings loss per share IFRS (5-year summary)
EPS (diluted)¥26.872021-01-01 → 2021-09-30Cons.Diluted earnings loss per share IFRS
EPS (diluted)¥7.322021-07-01 → 2021-09-30dCons.Diluted earnings loss per share IFRS
Equity ratio62.8%at 2022-09-30Cons.Ratio of owners equity to gross assets IFRS (5-year summary)
Equity ratio62.3%at 2021-12-31Cons.Ratio of owners equity to gross assets IFRS (5-year summary)
Equity ratio62.1%at 2021-09-30Cons.Ratio of owners equity to gross assets IFRS (5-year summary)

Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.

Segments · 26
SegmentItemPeriodValue
Reconciling Itemsreconcilingrevenue2022-01-01 → 2022-09-30−¥38m
Reconciling Itemsreconcilingrevenue intersegment2022-01-01 → 2022-09-30−¥38m
jpcrp040300-q3r_E05712-000Medical Devicereportable segmentrevenue2022-01-01 → 2022-09-30¥1.8bn
jpcrp040300-q3r_E05712-000Medical Devicereportable segmentrevenue external2022-01-01 → 2022-09-30¥1.7bn
jpcrp040300-q3r_E05712-000Medical Devicereportable segmentrevenue intersegment2022-01-01 → 2022-09-30¥38m
jpcrp040300-q3r_E05712-000Medical Devicereportable segmentsegment profit2022-01-01 → 2022-09-30¥699m
jpcrp040300-q3r_E05712-000Pharmaceuticalreportable segmentrevenue2022-01-01 → 2022-09-30¥11.0bn
jpcrp040300-q3r_E05712-000Pharmaceuticalreportable segmentrevenue external2022-01-01 → 2022-09-30¥11.0bn
jpcrp040300-q3r_E05712-000Pharmaceuticalreportable segmentsegment profit2022-01-01 → 2022-09-30¥796m
—segment totalrevenue2022-01-01 → 2022-09-30¥12.8bn
—segment totalrevenue external2022-01-01 → 2022-09-30¥12.8bn
—segment totalrevenue intersegment2022-01-01 → 2022-09-30¥38m
—segment totalsegment profit2022-01-01 → 2022-09-30¥1.5bn
Reconciling Itemsreconcilingrevenue2021-01-01 → 2021-09-30−¥35m
Reconciling Itemsreconcilingrevenue intersegment2021-01-01 → 2021-09-30−¥35m
jpcrp040300-q3r_E05712-000Medical Devicereportable segmentrevenue2021-01-01 → 2021-09-30¥1.5bn
jpcrp040300-q3r_E05712-000Medical Devicereportable segmentrevenue external2021-01-01 → 2021-09-30¥1.5bn
jpcrp040300-q3r_E05712-000Medical Devicereportable segmentrevenue intersegment2021-01-01 → 2021-09-30¥35m
jpcrp040300-q3r_E05712-000Medical Devicereportable segmentsegment profit2021-01-01 → 2021-09-30¥547m
jpcrp040300-q3r_E05712-000Pharmaceuticalreportable segmentrevenue2021-01-01 → 2021-09-30¥8.1bn
jpcrp040300-q3r_E05712-000Pharmaceuticalreportable segmentrevenue external2021-01-01 → 2021-09-30¥8.1bn
jpcrp040300-q3r_E05712-000Pharmaceuticalreportable segmentsegment profit2021-01-01 → 2021-09-30¥1.4bn
—segment totalrevenue2021-01-01 → 2021-09-30¥9.6bn
—segment totalrevenue external2021-01-01 → 2021-09-30¥9.5bn
—segment totalrevenue intersegment2021-01-01 → 2021-09-30¥35m
—segment totalsegment profit2021-01-01 → 2021-09-30¥2.0bn

Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.

All source rows · 716
ItemContextValueUnit
Cost of sales IFRSPrior1YTDDuration1209298000JPY
Cost of sales IFRSCurrentYTDDuration1907239000JPY
Gross profit IFRSPrior1YTDDuration8327415000JPY
Gross profit IFRSCurrentYTDDuration10853792000JPY
Selling general and administrative expenses IFRSPrior1YTDDuration5503838000JPY
Selling general and administrative expenses IFRSCurrentYTDDuration7498561000JPY
Research and development expenditure recognized as expense during period IFRSPrior1YTDDuration1417656000JPY
Research and development expenditure recognized as expense during period IFRSCurrentYTDDuration1819132000JPY
Other income IFRSPrior1YTDDuration669317000JPY
Other income IFRSCurrentYTDDuration82623000JPY
Other expenses IFRSPrior1YTDDuration114776000JPY
Other expenses IFRSCurrentYTDDuration124524000JPY
Operating profit loss IFRSPrior1YTDDuration1960461000JPY
Operating profit loss IFRSCurrentYTDDuration1494197000JPY
Finance income IFRSPrior1YTDDuration69554000JPY
Finance income IFRSCurrentYTDDuration347752000JPY
Finance costs IFRSPrior1YTDDuration461276000JPY
Finance costs IFRSCurrentYTDDuration618870000JPY
Profit loss before tax IFRSPrior1YTDDuration1568739000JPY
Profit loss before tax IFRSCurrentYTDDuration1223079000JPY
Income tax expense IFRSPrior1YTDDuration693840000JPY
Income tax expense IFRSCurrentYTDDuration898662000JPY
Profit loss IFRSPrior1YTDDuration874898000JPY
Profit loss IFRSCurrentYTDDuration324416000JPY
Profit loss attributable to owners of parent IFRSPrior1YTDDuration1294290000JPY
Profit loss attributable to owners of parent IFRSCurrentYTDDuration1076065000JPY
Profit loss attributable to non controlling interests IFRSPrior1YTDDuration-419391000JPY
Profit loss attributable to non controlling interests IFRSCurrentYTDDuration-751649000JPY
Basic earnings loss per share IFRSPrior1YTDDuration27.69
Basic earnings loss per share IFRSCurrentYTDDuration22.67
Diluted earnings loss per share IFRSPrior1YTDDuration26.87
Diluted earnings loss per share IFRSCurrentYTDDuration22.46
Revenue IFRSPrior1QuarterDuration3071539000JPY
Revenue IFRSCurrentQuarterDuration4606213000JPY
Cost of sales IFRSPrior1QuarterDuration423606000JPY
Cost of sales IFRSCurrentQuarterDuration772584000JPY
Gross profit IFRSPrior1QuarterDuration2647932000JPY
Gross profit IFRSCurrentQuarterDuration3833629000JPY
Selling general and administrative expenses IFRSPrior1QuarterDuration1825913000JPY
Selling general and administrative expenses IFRSCurrentQuarterDuration2732811000JPY
Research and development expenditure recognized as expense during period IFRSPrior1QuarterDuration552720000JPY
Research and development expenditure recognized as expense during period IFRSCurrentQuarterDuration729592000JPY
Other income IFRSPrior1QuarterDuration249420000JPY
Other income IFRSCurrentQuarterDuration28243000JPY
Other expenses IFRSPrior1QuarterDuration13886000JPY
Other expenses IFRSCurrentQuarterDuration-90059000JPY
Operating profit loss IFRSPrior1QuarterDuration504832000JPY
Operating profit loss IFRSCurrentQuarterDuration489529000JPY
Finance income IFRSPrior1QuarterDuration36744000JPY
Finance income IFRSCurrentQuarterDuration171977000JPY

Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.

Data checks · 16 of 16 passed
balance sheet identityconsolidated 2021-12-31pass
balance sheet identityconsolidated 2022-09-30pass
dei present pass
period resolution pass
statement vs summary · net income attributable to parentconsolidated 2021-01-01/2021-09-30pass
statement vs summary · net income attributable to parentconsolidated 2021-07-01/2021-09-30pass
statement vs summary · net income attributable to parentconsolidated 2022-01-01/2022-09-30pass
statement vs summary · net income attributable to parentconsolidated 2022-07-01/2022-09-30pass
statement vs summary · operating cash flowconsolidated 2021-01-01/2021-09-30pass
statement vs summary · operating cash flowconsolidated 2022-01-01/2022-09-30pass
statement vs summary · revenueconsolidated 2021-01-01/2021-09-30pass
statement vs summary · revenueconsolidated 2021-07-01/2021-09-30pass
statement vs summary · revenueconsolidated 2022-01-01/2022-09-30pass
statement vs summary · revenueconsolidated 2022-07-01/2022-09-30pass
statement vs summary · total assetsconsolidated 2021-12-31pass
statement vs summary · total assetsconsolidated 2022-09-30pass